DPPX Epitope Polypeptide Autoimmune Encephalitis Detection

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current diagnostic methods fail to effectively identify autoimmune encephalitis of unknown etiology, leading to undiagnosed cases and inappropriate management.

Innovation Solution

A polypeptide or protein comprising at least one epitope derived from DPPX, a novel autoantigen, is used for the detection of autoimmune encephalitis, along with associated nucleic acids, vectors, cells, and test kits to facilitate accurate diagnosis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional diagnostic methods are used for encephalitis, then general encephalitis detection is possible, but autoimmune encephalitis cannot be specifically identified

Engineering Contradiction:
Improvedetection specificityVSAvoiddisease etiology information
Core Design Contradiction:
Measurement precisionVSLoss of information

Solution Approach 1:

The invention segments the diagnostic approach by introducing a specific polypeptide comprising epitopes from DPPX, LGI1, and CASPR2 antigens. This segmented approach allows detection of autoimmune encephalitis specifically, distinguishing it from other encephalitis forms through targeted antibody detection against these identified autoantigens.

Inventive Principle:
Principle #1Segmentation

2Reliability

If autoimmune encephalitis remains undiagnosed, then general medical management continues, but appropriate immunotherapy cannot be administered

Engineering Contradiction:
Improvetreatment appropriatenessVSAvoiddiagnosis time
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The invention performs preliminary action by pre-identifying and preparing diagnostic reagents (polypeptides with specific epitopes from DPPX, LGI1, and CASPR2) before clinical need arises. This allows immediate and accurate diagnosis when autoimmune encephalitis is suspected, enabling timely administration of appropriate immunotherapy without diagnostic delays.

Inventive Principle:
Principle #10Preliminary action

3Measurement precision

If novel autoantigens DPPX, LGI1, and CASPR2 are identified and used for detection, then autoimmune encephalitis can be specifically diagnosed, but diagnostic complexity increases

Engineering Contradiction:
Improvedisease identification accuracyVSAvoiddiagnostic system complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The invention merges multiple epitope-specific polypeptides (from DPPX, LGI1, and CASPR2 antigens) into a comprehensive diagnostic system. This combined approach detects multiple autoimmune encephalitis types simultaneously, improving diagnostic accuracy while managing complexity through an integrated test kit format that presents a unified diagnostic solution.

Inventive Principle:
Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables the identification of autoimmune encephalitis, distinguishing it from other forms of encephalitis or diseases, and allows for targeted immunotherapy and intensive care support, improving patient outcomes.

Implementation Method 1

a polypeptide or protein comprising at least one epitope derived from DPPX, a novel autoantigen for detection of autoimmune disorder

Methodology Applied
Scientific EffectAntigen-antibody binding:

Data Source

PatentEP2895507B1Diagnostic method for detecting an autoimmune disease and related subject-matter
Publication Date: 2018.11.14 INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ICREA)
  • EP2895507B1 patent drawingFigure 1A~1C
  • EP2895507B1 patent drawingFigure 2A
  • EP2895507B1 patent drawingFigure 2B~2BC

AI summary

The present invention relates to a polypeptide or protein for use in a method of diagnosis or treatment of an autoimmune disease in a subject, characterized in that said polypeptide or protein comprises one or more epitopes derived from the protein DPPX. Further, the invention relates to a nucleic acid or vector encoding such polypeptide, to a cell comprising such a vector, to an in vitro diagnostic method and test kit involving such polypeptide, to a pharmaceutical composition comprising such polypeptide, to a medical device coated with such polypeptide or pharmaceutical composition and to methods for treating an autoimmune disease in a subject.